NAV

Imidapril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Imidapril is an ACE inhibitor used in the treatment of essential hypertension.

Generic Name
Imidapril
DrugBank Accession Number
DB11783
Background

Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 405.4449
Monoisotopic: 405.189985611
Chemical Formula
C20H27N3O6
Synonyms
  • Imidapril
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofHypertension,essential••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbaloparatideThe risk or severity of adverse effects can be increased when Abaloparatide is combined with Imidapril.
AcebutololAcebutolol may increase the hypotensive activities of Imidapril.
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Imidapril.
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Imidapril.
Acetylsalicylic acidThe therapeutic efficacy of Imidapril can be decreased when used in combination with Acetylsalicylic acid.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Imidapril hydrochloride7NSF9GG1NU89396-94-1LSLQGMMMRMDXHN-GEUPQXMHSA-N

Categories

ATC Codes
C09AA16 — Imidapril
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / N-acyl ureas / Fatty acid esters / Aralkylamines / Imidazolidinones / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Dicarboximides
show 9 more
Substituents
Alpha-amino acid amide / Alpha-amino acid ester / Alpha-amino acid or derivatives / Alpha-dipeptide / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
BW7H1TJS22
CAS number
89371-37-9
InChI Key
KLZWOWYOHUKJIG-BPUTZDHNSA-N
InChI
InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
IUPAC Name
(4S)-3-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
SMILES
[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O

References

General References
  1. BPOM Drug Information: Imidapril monograph [Link]
  2. TITCK Product Information: Tanatril (imidapril hydrochloride) oral tablets [Link]
Human Metabolome Database
HMDB0041907
PubChem Compound
5464343
PubChem Substance
347828133
ChemSpider
4576628
BindingDB
50020400
RxNav
60245
ChEBI
135654
ChEMBL
CHEMBL317094
ZINC
ZINC000003784427
PharmGKB
PA452640
Wikipedia
Imidapril

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentHypertension, Essential Hypertension1
3Unknown StatusTreatmentHypertension / Microalbuminuria / Type 2 Diabetes Mellitus1
2Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease （ADPKD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderOral
TabletOral
TabletOral10 MG
TabletOral20 mg
TabletOral5 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.447 mg/mLALOGPS
logP0.74ALOGPS
logP-0.23Chemaxon
logS-3ALOGPS
pKa (Strongest Acidic)3.49Chemaxon
pKa (Strongest Basic)5.22Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area116.25 Å2Chemaxon
Rotatable Bond Count10Chemaxon
Refractivity103.2 m3·mol-1Chemaxon
Polarizability42.36 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-01p6-9522000000-2d7e7f1a0358d64215dc
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a59-0326900000-0b598578a262acb1eeaf
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-1026900000-4764d3fb3a5f5097d3cd
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-06sr-0879300000-0059996e07cd2f724c04
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01r6-7957100000-bc44413bedec2ff5f0f8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-004l-4912000000-d3fdd8b0b286bb0e6d0b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-2912000000-9222435b9e2741ae2365
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-214.7943631
predicted
DarkChem Lite v0.1.0
[M-H]-212.7553631
predicted
DarkChem Lite v0.1.0
[M-H]-182.50143
predicted
DeepCCS 1.0 (2019)
[M+H]+215.4916631
predicted
DarkChem Lite v0.1.0
[M+H]+212.8981631
predicted
DarkChem Lite v0.1.0
[M+H]+184.897
predicted
DeepCCS 1.0 (2019)
[M+Na]+214.7070631
predicted
DarkChem Lite v0.1.0
[M+Na]+212.8157631
predicted
DarkChem Lite v0.1.0
[M+Na]+190.80952
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 20:47 / Updated at May 14, 2021 01:12